| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047106483 |
| P356 | DOI | 10.1038/NRUROL.2016.26 |
| P698 | PubMed publication ID | 26902337 |
| P50 | author | Tobias Maurer | Q37830488 |
| P2093 | author name string | Markus Schwaiger | |
| Matthias Eiber | |||
| Jürgen E Gschwend | |||
| P2860 | cites work | [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice | Q85364606 |
| Overview of prostate-specific membrane antigen | Q95814834 | ||
| ESUR prostate MR guidelines 2012 | Q24620926 | ||
| Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure–activity relationship studies | Q27658096 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature | Q28139062 | ||
| Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents | Q28241000 | ||
| Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer | Q28254156 | ||
| Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene | Q28290465 | ||
| [(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery | Q30396825 | ||
| In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging | Q31085729 | ||
| Constitutive and antibody-induced internalization of prostate-specific membrane antigen. | Q32015731 | ||
| Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer | Q33464875 | ||
| Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase | Q33576278 | ||
| Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer | Q33645821 | ||
| A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen | Q33763004 | ||
| Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations | Q34035683 | ||
| Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. | Q34228828 | ||
| The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis | Q34317181 | ||
| 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. | Q34389457 | ||
| Guideline for the management of clinically localized prostate cancer: 2007 update. | Q34629234 | ||
| Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen | Q35035214 | ||
| The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer | Q35043569 | ||
| Pathological and molecular aspects of prostate cancer | Q35089533 | ||
| Degradation of halogenated aromatic compounds | Q35300216 | ||
| Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. | Q35604902 | ||
| Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. | Q51869828 | ||
| Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. | Q52989826 | ||
| First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT. | Q53012729 | ||
| Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. | Q53023502 | ||
| (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. | Q53040229 | ||
| Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? | Q53059256 | ||
| [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy. | Q53060499 | ||
| PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. | Q53131398 | ||
| Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? | Q53173525 | ||
| [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. | Q53176385 | ||
| Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. | Q53191334 | ||
| Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? | Q53272044 | ||
| Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. | Q53363420 | ||
| MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. | Q53398594 | ||
| Prostate adenocarcinoma presenting with inguinal lymphadenopathy. | Q53658262 | ||
| In vivo visualization of prostate-specific membrane antigen in glioblastoma. | Q55460684 | ||
| Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy | Q60606969 | ||
| Dynamic Contrast-enhanced–magnetic Resonance Imaging Evaluation of Intraprostatic Prostate Cancer: Correlation with Radical Prostatectomy Specimens | Q63966229 | ||
| Experience with carbon-11 choline positron emission tomography in prostate carcinoma | Q73010182 | ||
| Prostate-specific membrane antigen is produced in tumor-associated neovasculature | Q73121375 | ||
| Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen | Q73764231 | ||
| In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging | Q74690521 | ||
| Prostate-specific membrane antigen expression in normal and malignant human tissues | Q77553386 | ||
| Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL | Q80930595 | ||
| Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis | Q81999680 | ||
| Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis | Q82640665 | ||
| Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers | Q84487151 | ||
| Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature | Q84496609 | ||
| Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging | Q85056944 | ||
| Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer | Q35645376 | ||
| Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer | Q35938051 | ||
| Prostate-specific membrane antigen: evidence for the existence of a second related human gene | Q36081147 | ||
| Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging | Q36591016 | ||
| The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy | Q36689474 | ||
| Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer | Q37091554 | ||
| The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis | Q37104080 | ||
| Comparison between malignant and benign abdominal lymph nodes on diffusion-weighted imaging | Q37142476 | ||
| Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer | Q37254919 | ||
| Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study | Q37328891 | ||
| Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer | Q37350456 | ||
| Imaging of prostate cancer local recurrences: why and how? | Q37634367 | ||
| A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence | Q37641490 | ||
| 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients | Q37696901 | ||
| Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer | Q37709638 | ||
| The renaissance of the ⁶⁸Ge/⁶⁸Ga radionuclide generator initiates new developments in ⁶⁸Ga radiopharmaceutical chemistry | Q37768191 | ||
| The timing of salvage radiotherapy after radical prostatectomy: a systematic review | Q38026296 | ||
| Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. | Q38049420 | ||
| Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. | Q38059100 | ||
| 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients | Q38098441 | ||
| 11C-choline PET/CT and PSA kinetics | Q38098442 | ||
| PET imaging in prostate cancer: focus on prostate-specific membrane antigen | Q38099369 | ||
| The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis | Q38102842 | ||
| PET/MR in prostate cancer: technical aspects and potential diagnostic value | Q38109083 | ||
| Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature | Q38128388 | ||
| Early salvage radiotherapy following radical prostatectomy | Q38131109 | ||
| 1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy | Q38211143 | ||
| Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review | Q38278155 | ||
| Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. | Q38861197 | ||
| 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies | Q38862313 | ||
| Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer | Q39009150 | ||
| Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody. | Q39017235 | ||
| Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro | Q39018543 | ||
| Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates | Q39208254 | ||
| 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging | Q39389586 | ||
| A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). | Q39420655 | ||
| 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer | Q39449818 | ||
| Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer | Q39808317 | ||
| Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy | Q39895770 | ||
| Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma | Q40278887 | ||
| The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. | Q40621372 | ||
| Multimodal image-guided prostate fusion biopsy based on automatic deformable registration. | Q40857650 | ||
| Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. | Q40959799 | ||
| Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line | Q40995835 | ||
| Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). | Q41018658 | ||
| Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer | Q41038146 | ||
| Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line | Q41123022 | ||
| Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids | Q41297571 | ||
| Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer | Q41319390 | ||
| Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer | Q41582278 | ||
| Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis | Q41866423 | ||
| Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. | Q41903880 | ||
| N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer | Q41913170 | ||
| Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases | Q42456087 | ||
| ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer | Q43156292 | ||
| MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy | Q44119084 | ||
| Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. | Q44350528 | ||
| Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer | Q45038526 | ||
| PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer | Q45328377 | ||
| A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer | Q46181868 | ||
| Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients | Q46329056 | ||
| ¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. | Q46558981 | ||
| 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy | Q46586622 | ||
| The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. | Q46984864 | ||
| Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. | Q48193288 | ||
| Characterization of the enzymatic activity of PSM: comparison with brain NAALADase | Q48223680 | ||
| Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma | Q48332695 | ||
| Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase | Q48776887 | ||
| Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. | Q50613922 | ||
| Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. | Q51353518 | ||
| The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. | Q51578822 | ||
| PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. | Q51766972 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 226-235 | |
| P577 | publication date | 2016-02-23 | |
| P1433 | published in | Nature Reviews Urology | Q2079265 |
| P1476 | title | Current use of PSMA-PET in prostate cancer management | |
| P478 | volume | 13 |
| Q47693515 | (68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. |
| Q38895102 | 68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment |
| Q55397004 | 68 Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer. |
| Q39419798 | 68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review. |
| Q90121997 | 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617 |
| Q64924033 | 68Ga-PSMA-11 PET enables accurate detection of recurrent disease. |
| Q88563961 | 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer |
| Q37662685 | 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. |
| Q89848845 | 68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study |
| Q64912414 | 68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer. |
| Q47269407 | 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends |
| Q50138475 | 68Gallium-Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer |
| Q47438555 | 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer |
| Q55001788 | A Case of Well-differentiated Hepatocellular Carcinoma Identified on Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography. |
| Q33917903 | An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [(18) F]DCFPyL. |
| Q38657325 | Anatomic and Molecular Imaging in Prostate Cancer |
| Q52581725 | Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey. |
| Q51324448 | Best of the 2016 AUA Annual Meeting: Highlights From the 2016 American Urological Association Annual Meeting, May 6-10, 2016, San Diego, CA. |
| Q61452678 | Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies |
| Q48350715 | Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer |
| Q42324524 | Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD |
| Q57071079 | Clinical perspectives of PSMA PET/MRI for prostate cancer |
| Q37541876 | Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology |
| Q47362426 | Dendrimer-based contrast agents for PET imaging |
| Q36363280 | Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry |
| Q98623780 | Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4-5 index lesions undergoing radical prostatectomy |
| Q49803982 | Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer |
| Q96764719 | Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer |
| Q41870783 | Epididymal metastasis from prostate adenocarcinoma: An unusual and challenging diagnosis suspected in gallium-68 prostate-specific membrane antigen-positron emission tomography/computed tomography and histologically confirmed |
| Q100395448 | Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology |
| Q33668676 | Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse |
| Q59130946 | Evaluation of lymph node status in patients with urothelial carcinoma-still in search of the perfect imaging modality: a systematic review |
| Q46851666 | Exploring Metabolism In Vivo Using Endogenous 11C Metabolic Tracers |
| Q51251756 | Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: A method comparable to direct fluorination. |
| Q48263290 | Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer. |
| Q57112259 | Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology |
| Q57107850 | Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer |
| Q98471360 | Genetic alterations in the 3q26.31-32 locus confer an aggressive prostate cancer phenotype |
| Q38946874 | Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease |
| Q92119205 | Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers? |
| Q89823517 | Imaging for Metastasis in Prostate Cancer: A Review of the Literature |
| Q55259128 | Imaging for the selection and monitoring of men on active surveillance for prostate cancer. |
| Q90581932 | ImmunoPET: Concept, Design, and Applications |
| Q87653929 | Incidental Malignancies Identified During Staging for Prostate Cancer With 68Ga Prostate-specific Membrane Antigen HBED-CC Positron Emission Tomography Imaging |
| Q55112074 | Incremental value of 68-gallium-prostate-specific membrane antigen positron emission tomography/computed tomography in patients with abnormal prostate-specific antigen and benign transrectal ultrasound biopsy. |
| Q57178975 | Innovations in Instrumentation for Positron Emission Tomography |
| Q47724407 | Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma |
| Q37541860 | Mapping Sentinel Lymph Node Metastasis by Dual-probe Optical Imaging |
| Q92746978 | Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or… |
| Q58563291 | Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases |
| Q41862863 | Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT. |
| Q59797641 | Monosodium Glutamate Reduces Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model |
| Q38641232 | Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative |
| Q99623715 | NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer |
| Q47189682 | Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. |
| Q57110084 | National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting |
| Q36411076 | New advances in focal therapy for early stage prostate cancer |
| Q38757513 | New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography. |
| Q38977428 | Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations |
| Q91845148 | Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer |
| Q41683899 | Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer |
| Q34682187 | PET Imaging in Patients with Meningioma - Report of the RANO/PET Group. |
| Q38831029 | PET imaging of recurrent and metastatic prostate cancer with novel tracers |
| Q28078479 | PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives |
| Q94156367 | POSTER PRESENTATIONS |
| Q94230866 | POSTER PRESENTATIONS |
| Q39003089 | PSMA PET and Radionuclide Therapy in Prostate Cancer |
| Q33899288 | PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics |
| Q42335927 | PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet? |
| Q38638455 | Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia |
| Q38647632 | Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging |
| Q49474983 | Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography |
| Q50083619 | Positron Emission Tomography Using a GRPR Antagonist (68)Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients |
| Q57110351 | Positron emission tomography in prostate cancer: An update on state of the art |
| Q99562764 | Potential Receptors for Targeted Imaging of Lymph Node Metastases in Penile Cancer |
| Q43119026 | Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions |
| Q90464069 | Practice changing for prostate cancer: a vision of the future |
| Q47399411 | Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. |
| Q102323415 | Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens |
| Q88348354 | Prognostic impact of nodal relapse in definitive prostate-only irradiation |
| Q50194467 | Proposal of a Structured Reporting System for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging: PSMA-RADS Version 1.0. |
| Q28075610 | Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers |
| Q38665724 | Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study |
| Q58562204 | Prostate imaging features that indicate benign or malignant pathology on biopsy |
| Q65001493 | Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review. |
| Q37390674 | Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer |
| Q92967284 | Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer |
| Q64065989 | Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection |
| Q88981178 | Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG |
| Q98164567 | Radiopharmaceutical therapy in cancer: clinical advances and challenges |
| Q42320689 | Rare Sites of Metastases in Prostate Cancer Detected on Ga-68 PSMA PET/CT Scan-A Case Series |
| Q50071465 | Reassembly of 89 Zr-Labeled Cancer Cell Membranes into Multicompartment Membrane-Derived Liposomes for PET-Trackable Tumor-Targeted Theranostics. |
| Q92127039 | Recent advances of PET imaging in clinical radiation oncology |
| Q50034009 | Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
| Q89747695 | Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer |
| Q47115390 | Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients |
| Q48370675 | Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223. |
| Q39010629 | Sentinel node biopsy and lymphatic mapping in penile and prostate cancer |
| Q99207585 | Simultaneous integrated boost with stereotactic radiotherapy for dominant intraprostatic lesion of localized prostate cancer: a dosimetric planning study |
| Q60947524 | Single-cell analysis of tumors: Creating new value for molecular biomarker discovery of cancer stem cells and tumor-infiltrating immune cells |
| Q101564382 | Surgical management of high-risk, localized prostate cancer |
| Q47731005 | Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives |
| Q91050162 | Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer |
| Q47651094 | The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure? |
| Q49919217 | The use of PET/CT in prostate cancer |
| Q38952181 | The very-high-risk prostate cancer: a contemporary update |
| Q39342954 | Therapy assessment of bone metastatic disease in the era of 223radium. |
| Q98232230 | Three-tiered sub-classification system of high-risk prostate cancer in men managed with radical prostatectomy: Implications for treatment decision-making |
| Q97523718 | Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer |
| Q55379783 | Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review. |
| Q92988466 | Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting |
| Q28079444 | Updates of prostate cancer staging: Prostate-specific membrane antigen |
| Q52981861 | [Rectal mucosa metastasis in recurrent prostate cancer : (68)Ga-PSMA-PET/CT allows targeted salvage radiotherapy]. |
Search more.